Kala Bio (KALA) Return on Capital Employed (2017 - 2026)
Kala Bio (KALA) posted Return on Capital Employed of 324.1% for Q1 2026, down 22.17% sequentially from 265.29% in Q4 2025, and down 18663.0% YoY from N/an in Q1 2025.
Kala Bio (KALA) Return on Capital Employed (2017 - 2026) Analysis & Trends
Kala Bio has reported Return on Capital Employed for 10 years, with the latest figure at 324.1% in Q1 2026.
- Quarterly Return on Capital Employed fell 18663.0% year-over-year to 324.1% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 324.1% (down 18663.0% YoY) and the FY2025 annual result came in at 130.57%, down 2483.0% from the prior year.
- Return on Capital Employed eased to 324.1% in Q1 2026 per KALA's latest filing, from 265.29% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 1884.88% in Q3 2025 and troughed at 324.1% in Q1 2026.
- A 5-year average of 28.71% and a median of 121.1% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2025: Return on Capital Employed slumped 19891 bps in 2022, then soared 200598 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 134.89% in 2022, then soared by 41 bps to 79.03% in 2023, then tumbled by 37 bps to 108.35% in 2024, then sank by 145 bps to 265.29% in 2025, then declined by 22 bps to 324.1% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 324.1%, 265.29%, and 1884.88% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.95 Bn | 132.10 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.71 Bn | 60.52 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.45 Bn | 55.31 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.24 Bn | 37.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.64 Bn | 10.25 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 7.88% |
| 10 | Kala Bio | 10.06 Mn | 10.06 Mn | - | -324.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -324.10% |
| Dec 31, 2025 | -265.29% |
| Sep 30, 2025 | 1,884.88% |
| Jun 30, 2025 | -157.42% |
| Mar 31, 2025 | -137.48% |
| Dec 31, 2024 | -108.35% |
| Sep 30, 2024 | -121.10% |
| Jun 30, 2024 | -104.69% |
| Mar 31, 2024 | -93.66% |
| Dec 31, 2023 | -79.03% |
| Sep 30, 2023 | -75.31% |
| Jun 30, 2023 | -77.47% |
| Mar 31, 2023 | -90.21% |
| Dec 31, 2022 | -134.89% |
| Sep 30, 2022 | -262.26% |
| Jun 30, 2022 | -198.48% |
| Mar 31, 2022 | -143.24% |
| Dec 31, 2021 | -100.81% |
| Sep 30, 2021 | -63.35% |
| Jun 30, 2021 | -57.07% |